| 10.4501 -5.18 (-33.14%) | 03-02 14:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 24.55  |
1-year : | 33.26 |
| Resists | First : | 21.02 |
Second : | 28.47 |
| Pivot price | 21.78 |
|||
| Supports | First : | 8.96 |
Second : | 7.45 |
| MAs | MA(5) : | 18.3 |
MA(20) : | 22.8 |
| MA(100) : | 31.7 |
MA(250) : | 22.58 |
|
| MACD | MACD : | -2 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 4.6 |
D(3) : | 21.8 |
| RSI | RSI(14): 25.4 |
|||
| 52-week | High : | 71.5 | Low : | 7.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ QURE ] has closed below the lower bollinger band by 20.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ QURE ] is to continue within current trading range. Bollinger Bands are 9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.3 - 17.41 | 17.41 - 17.49 |
| Low: | 15.26 - 15.39 | 15.39 - 15.48 |
| Close: | 15.47 - 15.65 | 15.65 - 15.78 |
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Mon, 02 Mar 2026
uniQure NV (QURE) Q4 2025 Earnings Call Highlights: Breakthroughs and Challenges in Gene Therapy - GuruFocus
Mon, 02 Mar 2026
uniQure (NASDAQ:QURE) Sees Strong Trading Volume After Better-Than-Expected Earnings - MarketBeat
Mon, 02 Mar 2026
UniQure Says FDA Rejects AMT-130 Phase I/II Studies Data; Stock Plunges 42% - Nasdaq
Mon, 02 Mar 2026
uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Mon, 02 Mar 2026
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 62 (M) |
| Held by Insiders | 4.899e+007 (%) |
| Held by Institutions | 5.5 (%) |
| Shares Short | 12,000 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.5437e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 329.7 % |
| Return on Equity (ttm) | -13.9 % |
| Qtrly Rev. Growth | 1.575e+007 % |
| Gross Profit (p.s.) | 92.23 |
| Sales Per Share | -246.68 |
| EBITDA (p.s.) | -1.83806e+008 |
| Qtrly Earnings Growth | -4.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -153 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 1.8 |
| Dividend | 0 |
| Forward Dividend | 1.14e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|